AU Patent

AU2020378619B2 — Combined therapy for muscular diseases

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2026-03-05 · 0y expired

What this patent protects

The present invention relates to the treatment of muscular diseases.

USPTO Abstract

The present invention relates to the treatment of muscular diseases.

Drugs covered by this patent

nusinersen-sodium (NUSINERSEN SODIUM)

Patent Metadata

Patent number: AU2020378619B2
Jurisdiction: AU
Classification: —
Expires: 2026-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Institut National de la Sante et de la Recherche Medicale INSERM
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.